TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30219482

Group type: EXPERIMENTAL
Intervention: Modified soap bar with embedded toys, delivered in a fun, interactive household session with minimal messaging.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plain soap delivered in a standard health-based hygiene promotion session.
Number of subjects: 80
Study: 27490823

Group type: EXPERIMENTAL
Intervention: Ai Chi
Number of subjects: 32

Group type: COMPARATOR
Intervention: IBAT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: APT (both Ai Chi and IBAT)
Number of subjects: 32
Study: 25694207

Group type: EXPERIMENTAL
Intervention: Early renal replacement therapy (RRT) initiated after 6 hours of urine output less than 0.5 ml/kg/h
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Late renal replacement therapy (RRT) initiated after persistent (>12 h) oliguria
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Subgroup analysis of patients with preoperative renal dysfunction and CS‐AKI
Number of subjects: 1658
Study: 23644347

Group type: EXPERIMENTAL
Intervention: Transbuccal delivery of Naltrexone using IntelliDrug device
Number of subjects: 12

Group type: COMPARATOR
Intervention: Per os administration of Naltrexone (50mg tablets)
Number of subjects: 12
Study: 21437607

Group type: EXPERIMENTAL
Intervention: Resting condition (28°C with 50% RH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Passive heating condition (28°C with 50% RH; leg immersion in a hot tub at 42°C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active heating condition (32°C with 70% RH; bicycle exercise)
Number of subjects: 20
Study: 19934287

Group type: EXPERIMENTAL
Intervention: Telomere length measured by monochrome multiplex quantitative PCR
Number of subjects: 214
Study: 17822977

Group type: EXPERIMENTAL
Intervention: Periocular corticosteroid injection before photodynamic therapy (PDT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: PDT alone (no corticosteroid)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Periocular corticosteroid injection before PDT
Number of subjects: 67
Study: 15147802

Group type: EXPERIMENTAL
Intervention: Three pharmaceutical preparations with different tablet disintegration times
Number of subjects: 0
Study: 11403536

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) as part of H. pylori eradication therapy
Number of subjects: 0
Study: 9742976

Group type: EXPERIMENTAL
Intervention: Intensive treatment with sulphonylureas or insulin
Number of subjects: 3867

Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 3867

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 3867

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 3867

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 3867

Group type: EXPERIMENTAL
Intervention: Intensive treatment (overall)
Number of subjects: 3867
Study: 8048498

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) + Spironolactone (Spi) (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) + Mifepristone (Mif) (400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3053314

Group type: EXPERIMENTAL
Intervention: Oral testosterone treatment
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Reduction of ethanol consumption
Number of subjects: 221
Study: 1101838

Group type: EXPERIMENTAL
Intervention: Spironolactone (300 to 450 mg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31221931

Group type: EXPERIMENTAL
Intervention: Yoga intervention (10 weeks, 3 sessions per week, 60 minutes each session)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no yoga intervention)
Number of subjects: 62
Study: 28259496

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy (SMT)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Integrative Acupuncture and SMT
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 3
Study: 26459336

Group type: EXPERIMENTAL
Intervention: Seasonal unconditional cash transfers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fresh food vouchers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care provided by the ACF programme
Number of subjects: 0
Study: 22544562

Group type: EXPERIMENTAL
Intervention: 10-month program of tailored materials designed to increase fruit and vegetable (F&V) intake, decrease fat intake, and/or increase physical activity (PA)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Change in self-efficacy for physical activity (PA)
Number of subjects: 543
Study: 21300181

Group type: EXPERIMENTAL
Intervention: Replication‐Competent Adenovirus‐mediated Suicide Gene Therapy followed by radiation (Arm 1)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Radiation alone (Arm 2)
Number of subjects: 280
Study: 19671200

Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 10
Study: 17201456

Group type: EXPERIMENTAL
Intervention: Rosiglitazone with rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone with rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone with gemfibrozil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone with gemfibrozil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosiglitazone and pioglitazone
Number of subjects: 0
Study: 15587768

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 752

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 752
Study: 11181193

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Alarm
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Alarm plus desmopressin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Desmopressin (for nonresponders)
Number of subjects: 84
Study: 9273185

Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and radiotherapy (cisplatin 50 mg/m2 on days 1 and 2, fluorouracil 1 gr/m2 continuous infusion on days 1, 2, and 3, external beam irradiation 20 Gy in 2 Gy fractions from days 1 to 12)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and radiotherapy
Number of subjects: 39
Study: 7962895

Group type: EXPERIMENTAL
Intervention: Posterior resin-bonded bridges (PRBBs) placed in maxilla
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Posterior resin-bonded bridges (PRBBs) placed in mandible
Number of subjects: 45
Study: 2440632

Group type: EXPERIMENTAL
Intervention: Propafenone (300 mg three times a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Disopyramide (200 mg three times a day)
Number of subjects: 10
Study: 29127949

Group type: EXPERIMENTAL
Intervention: Ranibizumab plus intravitreous dexamethasone implant (700 μg)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ranibizumab (0.3 mg) alone
Number of subjects: 116
Study: 26091907

Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate+golimumab)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Methotrexate-monotherapy
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 12-week MRI
Number of subjects: 234

Group type: COMPARATOR
Intervention: 1-year X-ray
Number of subjects: 234

Group type: COMPARATOR
Intervention: 52-week vdHS
Number of subjects: 234
Study: 25172879

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (daily motivational messages about nutrition and physical activity)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (paper-based information about healthy lifestyle)
Number of subjects: 100
Study: 23649400

Group type: EXPERIMENTAL
Intervention: Single-bone intramedullary fixation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both-bone intramedullary fixation
Number of subjects: 24
Study: 20723012

Group type: EXPERIMENTAL
Intervention: Zirconia fixed dental prostheses with preliminary mechanical damage (defined saw cuts)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zirconia fixed dental prostheses without preliminary damage (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zirconia fixed dental prostheses (both damaged and undamaged) subjected to artificial aging by TMC
Number of subjects: 40
Study: 19020127

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study: 15779328

Group type: EXPERIMENTAL
Intervention: Selective attention to target stimuli
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive observation of visual symbols
Number of subjects: 11
Study: 14699230

Group type: EXPERIMENTAL
Intervention: Actinomadura vinacea (provisionally identified)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Actinomadura pelletieri (known red grain mycetoma agent)
Number of subjects: 2
Study: 12612294

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 16 weeks
Number of subjects: 639

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study: 10447578

Group type: EXPERIMENTAL
Intervention: Nolatrexed 725 mg/m(2)/day by continuous infusion for 5 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m(2) as rapid intravenous infusion every 3 weeks
Number of subjects: 54
Study: 7783102

Group type: EXPERIMENTAL
Intervention: Insulin infusion (7.1 pM/kg per min) during euglycemic hyperinsulinaemic glucose clamp
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fasting intracellular (erythrocyte) magnesium concentrations
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin concentrations
Number of subjects: 37
Study: 2245049

Group type: EXPERIMENTAL
Intervention: Plegisol
Number of subjects: 50

Group type: COMPARATOR
Intervention: O2-Plegisol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 569995

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg IV
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo IV
Number of subjects: 116
Study: 31965358

Group type: EXPERIMENTAL
Intervention: Statistical Volume Element (SVE) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Representative Volume Element (RVE) model
Number of subjects: 0
Study: 31786228

Group type: EXPERIMENTAL
Intervention: Short-term stenting (1 week)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard stenting (4 weeks)
Number of subjects: 37
Study: 27324337

Group type: EXPERIMENTAL
Intervention: non-opioid/opioid analgesic combinations plus topical 0.25% bupivacaine onto the cystic plate and local 0.25% bupivacaine port-site injection
Number of subjects: 63

Group type: COMPARATOR
Intervention: non-opioid/opioid analgesic combinations (Control Group)
Number of subjects: 63
Study: 26445140

Group type: EXPERIMENTAL
Intervention: Mepolizumab 12.5 mg SC
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mepolizumab 125 mg SC
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mepolizumab 250 mg SC
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mepolizumab 75 mg IV
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mepolizumab SC doses providing 50% inhibition
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mepolizumab SC doses providing 90% inhibition
Number of subjects: 70
Study: 23407222

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 20670958

Group type: EXPERIMENTAL
Intervention: Fixed-dose MMF therapy
Number of subjects: 901

Group type: COMPARATOR
Intervention: Concentration-controlled MMF therapy
Number of subjects: 901
Study: 19810000

Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support (CDS) system
Number of subjects: 599

Group type: COMPARATOR
Intervention: No computerized clinical decision support (CDS) system
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Adherers to EBPG
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Non-adherers to EBPG
Number of subjects: 599
Study: 16625234

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 4159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study: 15659929

Group type: EXPERIMENTAL
Intervention: Standard transurethral resection of prostate (TURP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transurethral vaporesection (TUVRP) with various loops
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard TURP and TUVRP
Number of subjects: 50
Study: 11742962

Group type: EXPERIMENTAL
Intervention: Multiple daily T‐piece weaning or pressure support
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Early extubation with back‐up noninvasive positive‐pressure ventilation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation
Number of subjects: 16
Study: 9264481

Group type: COMPARATOR
Intervention: Heparin (5000 IU bolus + 1000 to 1200 U/h infusion, n=371)
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Low-dose hirudin (0.2 mg/kg bolus + 0.10 mg x kg(‐1) x h(‐1) infusion, n=271)
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Medium-dose hirudin (0.4 mg/kg bolus + 0.15 mg x kg(‐1) x h(‐1) infusion, n=267)
Number of subjects: 909
Study: 8219662

Group type: EXPERIMENTAL
Intervention: Preparation A (pH 8.0)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preparation C (pH 10.2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single doses of preparations A and E
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 30
Study: 29673465

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 23953

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 23953

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 23953

Group type: EXPERIMENTAL
Intervention: Ibuprofen with aspirin
Number of subjects: 23953

Group type: EXPERIMENTAL
Intervention: Naproxen with aspirin
Number of subjects: 23953
Study: 27888995

Group type: EXPERIMENTAL
Intervention: NIV plus oxygen therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 18
Study: 24722649

Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 21
Study: 23006736

Group type: EXPERIMENTAL
Intervention: Allopurinol (xanthine oxidase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probenecid (uricosuric)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20799399

Group type: EXPERIMENTAL
Intervention: Immunovac‐VP4 vaccine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combination therapy with Immunovac‐VP4 vaccine
Number of subjects: 69
Study: 18388929

Group type: EXPERIMENTAL
Intervention: NV1FGF (2.5 ml at 0.2 mg/ml, 8 intramuscular injections on days 1, 15, 30, and 45)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: NV1FGF
Number of subjects: 125
Study: 15727045

Group type: EXPERIMENTAL
Intervention: Virtual reality play
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nine VR environments
Number of subjects: 16
Study: 12775947

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study: 10727077

Group type: EXPERIMENTAL
Intervention: Vitamin antioxidant mixture (600 mg alpha‐tocopherol, 1,000 mg vitamin C, 32 mg beta‐carotene)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8889119

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise (1 hour of treadmill walking at 50% maximum oxygen uptake)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol and Metoprolol
Number of subjects: 0
Study: 1510435

Group type: EXPERIMENTAL
Intervention: Intravenous administration of ceftazidime (1-g dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Endotracheal administration of ceftazidime (1-g dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aerosol administration of ceftazidime (1-g dose)
Number of subjects: 12
Study: 6091247

Group type: EXPERIMENTAL
Intervention: ACTH 1‐17
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30935665

Group type: EXPERIMENTAL
Intervention: Participants with persistent indoor-air-related symptoms
Number of subjects: 52

Group type: COMPARATOR
Intervention: General population (comparison group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Individuals with asthma (comparison group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Individuals with anxiety and depressive disorder (comparison group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Individuals with chronic conditions with work disability (comparison group)
Number of subjects: 52
Study: 29722796

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 396
Study: 26079866

Group type: EXPERIMENTAL
Intervention: Spine orthoses (Vertebradyn‐Strong)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spine orthoses (Horizon 637 LSO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spine orthoses (SofTec Dorso)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hip orthoses (DynaCox and Hohmann‐like orthosis)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All orthoses
Number of subjects: 30
Study: 25376414

Group type: EXPERIMENTAL
Intervention: E-health intervention designed to reduce prolonged occupational sitting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 22139751

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs‐cTnT) measured at randomization and after 3 months (GISSI‐HF) or 4 months (Val‐HeFT) follow-up.
Number of subjects: 5284

Group type: EXPERIMENTAL
Intervention: Changes in hs‐cTnT concentration over time.
Number of subjects: 5284
Study: 20197487

Group type: EXPERIMENTAL
Intervention: 350 mg, 700 mg, 1400 mg, or 2100 mg of artemisinin-naphthoquine phosphate
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of artemisinin and naphthoquine phosphate
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Food intake
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single oral dose administration
Number of subjects: 28
Study: 17905357

Group type: EXPERIMENTAL
Intervention: GengNianAn (GNA) formula, taken twice daily for 12 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo, taken twice daily for 12 weeks
Number of subjects: 69
Study: 14999424

Group type: EXPERIMENTAL
Intervention: Hyaluronan
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11905547

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 200 microg metered dose inhaler (MDI) administered by Fluspacer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9527090

Group type: EXPERIMENTAL
Intervention: Radial approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Brachial approach
Number of subjects: 100
Study: 7843761

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 1.25 mg ramipril
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 2146282

Group type: EXPERIMENTAL
Intervention: DHEA (1600 mg/day, orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31757

Group type: EXPERIMENTAL
Intervention: Morphine anaesthesia (4 mg/kg before skin incision)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fluroxene anaesthesia
Number of subjects: 12
Study: 31499206

Group type: EXPERIMENTAL
Intervention: Single-dose rifampicin (SDR) after BCG vaccination
Number of subjects: 14988

Group type: COMPARATOR
Intervention: BCG vaccination only (Control)
Number of subjects: 14988
Study: 28190236

Group type: EXPERIMENTAL
Intervention: Supportive educational intervention for carers including initial telephone assessment, personalized resource file, nurse-led home visit, ongoing telephone support
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Care-IS intervention
Number of subjects: 10
Study: 27502846

Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 12944

Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 12944

Group type: EXPERIMENTAL
Intervention: No/trace albuminuria
Number of subjects: 12944
Study: 24880843

Group type: EXPERIMENTAL
Intervention: Aligners with attachment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aligners without attachment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aligners for maxillary incisor torque
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aligners for distalization
Number of subjects: 30
Study: 22326605

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (11 severely obese patients with asthma)
Number of subjects: 12
Study: 20101064

Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg mixed with applesauce
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg mixed with grape jelly
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg mixed with yogurt
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg mixed with infant formula
Number of subjects: 24

Group type: COMPARATOR
Intervention: efavirenz 600 mg intact capsules under fasting conditions
Number of subjects: 24
Study: 17621027

Group type: EXPERIMENTAL
Intervention: Dexanabinol
Number of subjects: 861
Study: 16723021

Group type: EXPERIMENTAL
Intervention: Phone based intervention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet based intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12438046

Group type: EXPERIMENTAL
Intervention: On-site mobile mammography and health education
Number of subjects: 499

Group type: COMPARATOR
Intervention: Health education only
Number of subjects: 499